Breaking News

Aridis Acquires Kenta mAb Portfolio

May 17, 2013

Includes six anti-infectives

Aridis has entered an agreement with Kenta Biotech to acquire Kenta's portfolio of anti-infective human monoclonal antibody (mAb) products and technologies. The portfolio includes six anti-infectives for the treatment of infections by common pathogens including drug resistant bacterial strains of Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter baumannii and respiratory syncytial virus (RSV). Two candidates are in Phase IIa trials for acute pneumonia.
 
Aridis founder and president Eric Patzer said, "We are pleased to complete this transaction and build upon the substantial financial investment and remarkable progress that our colleagues at Kenta Biotech have achieved in creating a portfolio of innovative products.”
 
Kenta chief executive officer Franco Merckling said, "We are pleased to have identified Aridis as the ideal partner to further develop the Kenta technology and project pipeline which has been built over the last seven years. Aridis, a leading San Francisco-area biotech company specializing in novel anti-infectives, is poised to accelerate the development of our drug candidates in both the U.S. and Europe.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.